For research use only. Not for therapeutic Use.
L-threo-sphingosine C-18(Cat No.:I011745) has been identified as a p38 MAPK inhibitor. P38 MAPK is a protein kinase that plays a role in various cellular processes, including inflammation, apoptosis, and cell differentiation. By inhibiting p38 MAPK, L-threo-sphingosine C-18 may have potential therapeutic applications in treating inflammatory diseases such as arthritis, psoriasis, and inflammatory bowel disease. In addition to its role as a p38 MAPK inhibitor, L-threo-sphingosine C-18 also has other biological activities, including antimicrobial, antitumor, and immunomodulatory effects.
Catalog Number | I011745 |
CAS Number | 25695-95-8 |
Synonyms | 2S-amino-4E-octadecene-1,3S-diol |
Molecular Formula | C18H37NO2 |
Purity | ≥95% |
Target | Apoptosis |
Solubility | Soluble in DMSO |
Storage | Store at -20°C |
IUPAC Name | (E,2S,3S)-2-aminooctadec-4-ene-1,3-diol |
InChI | InChI=1S/C18H37NO2/c1-2-3-4-5-6-7-8-9-10-11-12-13-14-15-18(21)17(19)16-20/h14-15,17-18,20-21H,2-13,16,19H2,1H3/b15-14+/t17-,18-/m0/s1 |
InChIKey | WWUZIQQURGPMPG-DNWQSSKHSA-N |
SMILES | CCCCCCCCCCCCC/C=C/[C@@H]([C@H](CO)N)O |
Reference | <br>1. Y. Hannun et al. “Stereoselectivity of Induction of the Retinoblastoma Gene Product (pRb) Dephosphorylation by D-erythro-Sphingosine Supports a Rolefor pRb in Growth Suppression by Sphingosine” Biochemistry, vol. 34 pp. 1885-1892, 1995<br>2. C. King et al. “Sphingosine Is a Novel Activator of 3-Phosphoinositide-dependent Kinase 1” The Journal of Biological Chemistry, vol. 275(24) pp.18108-18113, 2000<br>3. S. Spiegel et al. “Stereospeci~cityo f Sp~ingosine-indu~eIdnt racellular Calcium Mobilization and Cellular Proliferation” Journal of BiologicalChemistry, vol. 269 pp. 17924-17930, 1994<br>4. V. Stevens et al. “Structural requirements for long-chain (sphingoid) base inhibition of protein kinase C in vitro and for the cellular effects of thesecompounds” Biochemistry, vol. 28, 3138-3145, 1989</br></br></br></br> |